Newly launched company, Verdiva Bio, is aiming to advance oral and injectable drugs for obesity, with it backed by an ...
The newly launched biotech is equipped with rights to a trio of weight loss medicines licensed from China-based Sciwind ...
GlobalData on MSN14d
UK-based Verdiva launches with $410m and an oral GLP-1RA candidateFinancing was co-led by Forbion and General Atlantic, with participants such as RA Capital Management, OrbiMed, and Lilly ...
Investor interest in companies with obesity candidates in their pipeline clearly remains high, given that a brand new ...
We recently compiled a list of the 9 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Eli ...
The Centers for Medicare and Medicaid Services (CMS) released its second round of drug negotiation targets, a list of 15 drugs under Medicare Part D, including Novo Nordisk's (NVO) blockbuster GLP-1s.
In a report released today, James Quigley from Goldman Sachs maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price target of DKK875.00. The company’s shares closed ...
NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Novo ...
Medicare has announced 15 new drugs up for price negotiations, set to begin in the next several months with top drugmakers, ...
The Centers for Medicare and Medicaid Services (CMS) released its second round of drug negotiation targets, a list of 15 drugs under Medicare Part D, including Novo Nordisk's (NVO) blockbuster GLP-1s.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback